301325 KBC LI Dynamic RI
LU2607047375 · Comfort Plus Shares Capitalisation · EUR
▲ +9.1%
6M return
← Edit selection
Comparing 2 funds
Returns, costs and exposure side by side, with sources and dates below.
North America
BE0126162628 · Classic Shares · USD
▲ +17.3%
6M return
Performance, starting at 100
GBP total return, daily prices to 21 Oct 2026. Source: FE fundinfo. Past performance is not a reliable guide to future returns.
If you had invested £10,000
What it would have become over 6M, GBP, month end to 30 Sep 2026.
Based on month end returns. Illustrative, before tax, not a prediction.
Country exposure
Average share of portfolio across these funds, as at 6 Oct 2026.
Not available for: 301325 KBC LI Dynamic RI.
Sector exposure
Average share of portfolio across these funds, as at 6 Oct 2026.
Not available for: 301325 KBC LI Dynamic RI.
AI comparison
AI assisted, not advice. Describes the data on this page.
Select Summarise differences for a short, neutral description of how these funds differ on the figures below.
Side by side
Returns in GBP, month end to 30 Sep 2026. Bold marks the highest value in the return rows, the lowest in the ongoing charge row and the largest in the fund size row.
| Metric | 301325 KBC LI Dynamic RI | North America |
|---|---|---|
| 1 year returnHighest in bold | ▲ +8.0% | ▲ +17.7% |
| 3 year returnHighest in bold | ▲ +33.2% | ▲ +61.2% |
| 5 year returnHighest in bold | n/a | ▲ +64.8% |
| Rank among sector peers, 1 yearQuartile among representative funds in the FE sector | Q4 of 3,301 representative funds | Q2 of 392 representative funds |
| Ongoing charge (OCF) | ||
| Fund size, GBPLargest in bold | £4.7B | £2.0B |
| Volatility, 1 year FE, as at 5 Jul 2026 | 9.3% | 14.0% |
| Sharpe ratio, 1 year FE, as at 5 Jul 2026 | 1.28 | 1.47 |
| Style | n/a | Active |
| FE sector | GL Multi-Asset Global Aggressive | GL Equity North America |
| Share class | Comfort Plus Shares Capitalisation · EUR | Classic Shares · USD |
Source: FE fundinfo, as supplied; the date shown is when FE last updated them.